27F, 1320-10, Seocho 2-dong, Seocho-gu
74 articles with Samsung Biologics
Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate
Samsung Biologics, the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins.
Samsung Biologics to add mRNA vaccine drug substance manufacturing suite to expand portfolio of services
Samsung Biologics, a global leading CDMO, will add mRNA vaccine DS production capability to its existing facility by the first half of 2022
Samsung Biologics Adds Four Global ISO Certifications For BCMS, Energy, Health & Safety, and Environmental Management
Expanding upon its existing ISO22301 certification, Samsung Biologics is now fully certified with Business Continuity Management System for Security and Resilience across all business areas Samsung Biologics adds ISO50001, ISO45001, ISO14001 for Energy Management, Occupational Health and Safety, and Environmental Management to its certifications
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine
The agreement will further enable global supply of mRNA-1273, Moderna's COVID-19 vaccine with Samsung Biologics' fill and finish manufacturing service
4/29/2021Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Samsung Biologics, the world's leading contract development and manufacturing organization, announced financial results for the first quarter of fiscal 2021.
Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab
Expanding upon an existing contract manufacturing deal first entered into in 2018; collaboration will further enable global manufacturing of ublituximab
Samsung Biologics, the world's leading contract development and manufacturing organization, celebrated the 10 th anniversary of its founding today at its global headquarters in Songdo, Incheon via a virtual ceremony.
Samsung Biologics Unveils Strong Performance and Future Plans at its 10th Annual General Meeting of Shareholders
Samsung Biologics announced a strong year in 2020 as it reported 1 trillion won in target sales within just a decade at its 10th Annual General Meeting on March 19th Korea time.
Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company's track record as a premiere CDO service provider in the global market.
Samsung Biologics reported its fourth quarter and full-year 2020 financial results indicating strong business performance, benefitting from increased sales across all plants and significant business agility and operating excellence in overcoming various challenges and global uncertainties amid the COVID-19 pandemic throughout the year.
Samsung Biologics Shares 'Vision' for Next Decade at the 39th Annual JP Morgan Healthcare Conference
Samsung Biologics (207940.KS) set forth its dynamic growth plan for the next decade at the 2021 Annual JP Morgan Healthcare Conference. John Rim , newly appointed President and CEO, unveiled a multidimensional business plan for the company to further expand as a major player in the biopharmaceutical industry, bolstering its
On Wednesday, Sage Therapeutics and Samsung Biologics announced that they had found just that in their new chief executive officers.
Samsung Biologics announced the launch of a virtual showroom to provide key features and real-time construction updates of its recently announced Plant 4.
Samsung Biologics breaks ground on Super Plant, the world's largest and most innovative bio-manufacturing facility
Samsung Biologics officially began construction of its Plant 4 in Incheon, South Korea.
Samsung Biologics announces strategic manufacturing partnership with Lilly to accelerate delivery of COVID-19 antibody treatments
Samsung Biologics' partnership with Eli Lilly and Company is expected to greatly accelerate the global supply for Lilly's COVID-19 antibody therapies through a long-term manufacturing agreement, with the ultimate goal of making antibody treatments more globally accessible for patients.
Samsung Biologics' Virtual Exhibition Hall earns top industry award for digital creativity and innovation
Samsung Biologics' Virtual Exhibition Hall was recently recognized for its highly interactive digital capabilities and virtual reality technology to connect with clients around the world.
The life sciences industry is one of the fastest growing in the world. BioSpace provides a rundown of companies announcing facility and job expansions across the U.S. and beyond.
Samsung Biologics Establishes Partnership with China Biotech GeneQuantum Healthcare to Collaborate on ADC Development
Samsung Biologics has entered into a strategic partnership with GeneQuantum Healthcare, a China biotech company, to jointly develop an antibody drug conjugate for the treatment of non-small-cell lung carcinoma, triple-negative breast cancer, and other solid tumors.
Samsung Biologics Co., Ltd. and Checkpoint Therapeutics, Inc., announced the expansion of a long-term manufacturing partnership for Checkpoint's anti-PD-L1 antibody, cosibelimab.